Previous research demonstrated that the IL-6/JAK–STAT3 pathway is aberrantly hyperactivated in many carcinomas, and hyperactivation was generally associated with unfavorable clinical prognosis [40]. The gene discussed is STAT3; the disease is carcinoma.